Research funder · United States
Children's Tumor Foundation
Foundation dedicated to improving the health and well-being of individuals and families affected by neurofibromatosis
- Grants since 2016
- 436
- Awarded, last 5 years (where amounts are published)
- 28.1M
- Funded works, last 5 years
- 115
- Funded works, all time
- 426
Grants
2016–2019 · award
NFCN - SSM Health Cardinal Glennon Children's Hospital
Ali Jamal
2016–2019 · award
NFCN - University of Oklahoma Health Sciences Center
Ashley Taylor
2016–2021 · award
Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma
Duncan Stearns
2016–2019 · award
NFCN - The Ohio State University
Oliver Adunka
2016–2018 · award
The Relaxation Response Resiliency Program for patients with NF2 who are deaf or have severe hearing loss
Ana-Maria Vranceanu
2016–2019 · award
NFCN - Nationwide Children's Hospital
Kandamurugu Manickam
2016–2019 · award
NFCN - CHOC Children's Hospital
Neda Zadeh
2016 · award
Phenotypic Screening Library Analysis for The Children's Tumor Foundation (Project Description Proposal 1 - EVTO4681
Itta Macnevin
2016–2019 · award
NFCN - University of Alabama at Birmingham
Bruce Korf
2016–2018 · award
TRAPping the metabolic adaptations of NF1-associated tumors
Ionica Masgras
2016–2019 · award
NFCN - Cincinnati Children's Hospital Medical Center
Elizabeth Schorry
2016–2021 · award
Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma
Natasha Pillay Smiley
2016–2019 · award
NFCN - Children's National Health System
Miriam Bornhorst
2016–2019 · award
NFCN - M Health - University of Minnesota Medical Center and Masonic Children's Hospital
Chris Moertel
2016–2019 · award
NFCN - UT Southwestern/Children's Health
Laura Klesse
2016–2019 · award
NFCN - New York Presbyterian Morgan Stanley Children's Hospital Columbia University Medical Center
Wendy Chung
2016–2018 · award
Dermal Neurofibromas Stereology Study
Steven Carroll
2016–2019 · award
NFCN - Cleveland Clinic Foundation
Manikum Moodley
2016–2017 · award
Targeting the mitochondrial chaperone TRAP1 to inhibit plexiform neurofibroma growth
Andrea Rasola
2016–2021 · award
Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma
Michael Brodsky
2016–2021 · award
Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma
Surya Rednam
2016–2018 · award
Preclinical safety and efficacy evaluation of long-term anti-VEGFA treatment administration in a GEM model of NF2-related schwannoma.
Marco Giovannini
2015–2020 · award
Synodos Low Grade Glioma
Joanna Phillips
2015–2020 · award
Synodods Low Grade Glioma
Michael Fisher
2015–2020 · award
International Schwannomatosis Database
Allan Belzberg
2015–2020 · award
Synodods Low Grade Glioma
Angela Waanders
2015–2020 · award
Synodos Low Grade Glioma
David Gutmann
2015–2020 · award
Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma
Michael Fisher
2015–2021 · award
Synodos – Innovative NF1 drug discovery pipeline for preclinical development of novel drugs quickly, safely, and effectively
David Largaespada
2015–2020 · award
A Study of INFUSE Bone Graft (recombinant human Bone Morphogenetic Protein-2/absorbable collagen sponge) in the Treatment of Tibial Pseudoarthrosis in Neurofibromatosis 1 (NF1)
Bruce Korf
2015–2020 · award
Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma
David Van Mater
2015–2020 · award
Synodos Low Grade Glioma
Stefan Pfister
2015–2021 · award
Improved Accessibility of NF Digital Image Archive and Metrics Service Renewal
Gordon Harris
2015–2020 · award
Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma
Laura Klesse
2013–2020 · award
The impact of Ras/MAPK signaling pathway-targeted therapies on neurocognitive functioning in youth with NF1.
Karin Walsh · Children's National
2012–2023 · award
Phase I Trial of the MEK Inhibitor AZD6244 in Children with NF1 and Inoperable Plexiform Neurofibromas
Michael Fisher · Children's Hospital of Philadelphia